Raymond L Woosley

Summary

Affiliation: The Critical Path Institute
Country: USA

Publications

  1. ncbi Is it possible for FDA regulatory scientists and industry scientists to work together?
    R L Woosley
    Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 91:390-2. 2012
  2. ncbi The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science
    R L Woosley
    Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 87:530-3. 2010
  3. ncbi They are from the government and they really are here to help you
    Raymond L Woosley
    The Critical Path Institute, Tucson, Arizona 85718, USA
    J Clin Pharmacol 48:142-3. 2008
  4. ncbi Drug development and the FDA's Critical Path Initiative
    R L Woosley
    The Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 81:129-33. 2007
  5. ncbi Gender and age differences in medications dispensed from a national chain drugstore
    Marietta Anthony
    The Critical Path Institute, Tucson, Arizona 85718, USA
    J Womens Health (Larchmt) 17:735-43. 2008
  6. ncbi Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium
    M Anthony
    The Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 86:425-9. 2009
  7. ncbi The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases
    K Romero
    Coalition Against Major Diseases, Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 86:365-7. 2009
  8. ncbi Potential drug-drug interactions within Veterans Affairs medical centers
    Maysaa Mahmood
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona UA, Tucson, AZ 85721 0202, USA
    Am J Health Syst Pharm 64:1500-5. 2007
  9. ncbi Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs
    Grant H Skrepnek
    College of Pharmacy, University of Arizona, Tucson, AZ 85721 0207, USA
    Ann Pharmacother 39:1785-91. 2005
  10. ncbi QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system
    Ellen C Pearson
    University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
    Pharmacoepidemiol Drug Saf 14:747-53. 2005

Research Grants

  1. Arizona Center for Education and Research on Therapeutics
    Raymond Woosley; Fiscal Year: 2007

Collaborators

Detail Information

Publications13

  1. ncbi Is it possible for FDA regulatory scientists and industry scientists to work together?
    R L Woosley
    Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 91:390-2. 2012
    ..quot;..
  2. ncbi The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science
    R L Woosley
    Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 87:530-3. 2010
    ..3)...
  3. ncbi They are from the government and they really are here to help you
    Raymond L Woosley
    The Critical Path Institute, Tucson, Arizona 85718, USA
    J Clin Pharmacol 48:142-3. 2008
  4. ncbi Drug development and the FDA's Critical Path Initiative
    R L Woosley
    The Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 81:129-33. 2007
    ..Clinical pharmacologists should be aware of these signals and their potential impact. Here, we discuss a strategy, where clinical pharmacology can play an important role to improve the process of drug development...
  5. ncbi Gender and age differences in medications dispensed from a national chain drugstore
    Marietta Anthony
    The Critical Path Institute, Tucson, Arizona 85718, USA
    J Womens Health (Larchmt) 17:735-43. 2008
    ..Our objective was to compare sex and age differences in the medications dispensed in pharmacies from a large national drugstore chain...
  6. ncbi Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium
    M Anthony
    The Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 86:425-9. 2009
    ..This study provides evidence that there is little concordance among commonly used drug compendia and product labels with respect to interactions involving warfarin...
  7. ncbi The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases
    K Romero
    Coalition Against Major Diseases, Critical Path Institute, Tucson, Arizona, USA
    Clin Pharmacol Ther 86:365-7. 2009
    ..The coalition's purpose is to transform the drug development paradigm for neurodegenerative diseases and serve as a model for other major diseases...
  8. ncbi Potential drug-drug interactions within Veterans Affairs medical centers
    Maysaa Mahmood
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona UA, Tucson, AZ 85721 0202, USA
    Am J Health Syst Pharm 64:1500-5. 2007
    ..This study assessed the prevalence of 25 clinically important drug-drug interactions (DDIs) in the ambulatory care clinics of the Department of Veterans Affairs medical centers (VAMCs)...
  9. ncbi Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs
    Grant H Skrepnek
    College of Pharmacy, University of Arizona, Tucson, AZ 85721 0207, USA
    Ann Pharmacother 39:1785-91. 2005
    ..Inappropriate medication use in patients with heart failure (HF) presents challenges in providing optimal, evidence-based care...
  10. ncbi QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system
    Ellen C Pearson
    University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
    Pharmacoepidemiol Drug Saf 14:747-53. 2005
    ..Recent case series have associated the synthetic opioid, methadone, with QT prolongation and torsades de pointes (TdP) ventricular arrhythmia...
  11. ncbi Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, P.O. Box 17969, Durham, NC 27715, USA
    Health Serv Res 41:837-55. 2006
    ..Future research should use individual-level data to assess whether these findings reflect a reduction in abuse and diversion or suboptimal treatment of pain...
  12. ncbi Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers
    Yu Ko
    Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
    Drug Saf 31:525-36. 2008
    ....
  13. ncbi Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients
    Lesley H Curtis
    Center for Clinical and Genetic Economics, Duke University Medical Center, Durham, North Carolina 27510, USA
    Am J Med 114:135-41. 2003
    ..Large pharmaceutical claims databases are useful for detecting potentially harmful prescribing behaviors, but better clinical evidence on medication safety is needed before such a system can be implemented fully...

Research Grants3

  1. Arizona Center for Education and Research on Therapeutics
    Raymond Woosley; Fiscal Year: 2007
    ..The AzCERT will leverage the federal funding for this grant through partnerships that extend our reach and our ability to improve health outcomes for patients. ..